)
Visual
earnings real time
Evommune (EVMN) investor relations material
Evommune Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary11 Dec, 2025
Executive summary
Completed IPO in November 2025, raising $172.5 million in gross proceeds, with net proceeds of $160.4 million, strengthening financial position for upcoming milestones.
Focused on developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 in Phase 2 trials for multiple indications including CSU, AD, and UC.
Anticipates three Phase 2 data readouts in 2026 for EVO756 and EVO301 targeting atopic dermatitis and chronic spontaneous urticaria.
Pipeline progress includes positive Phase 2 data for EVO756 in chronic inducible urticaria and ongoing expansion into additional indications.
Accumulated deficit reached $192.8 million as of September 30, 2025, with continued net losses expected as R&D and operational expenses increase.
Financial highlights
License revenue was $13.0 million for the nine months ended September 30, 2025, up from $7.0 million in the prior year period, driven by milestone payments from Maruho.
Revenue for Q3 2025 was $10.0 million, compared to zero in Q3 2024, driven by a licensing collaboration.
Net loss for the nine months ended September 30, 2025 was $40.6 million, compared to $46.1 million in the same period in 2024.
Research and development expenses increased to $53.6 million for the nine months ended September 30, 2025, primarily due to higher clinical trial and discovery research costs.
Cash, cash equivalents, and short-term investments totaled $76.1 million as of September 30, 2025, prior to IPO proceeds.
Outlook and guidance
Expects top-line Phase 2b data for EVO756 in CSU in the first half of 2026 and in AD in the second half of 2026.
Phase 2a data for EVO301 in AD anticipated in the first half of 2026.
Current cash, cash equivalents, short-term investments, and IPO proceeds are expected to fund operations into the second half of 2028.
Anticipates continued increases in R&D and G&A expenses as clinical programs advance and company scales operations.
No product revenue expected for several years; future funding needs will depend on clinical progress and milestone achievements.
Cash runway post-IPO, considering burn rate
EVO756's unique mechanism: competitive edge
Rationale for new EVO756/EVO301 indications
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Evommune earnings date
Q4 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage